The short version of Ac-LKKTETQ fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-16. Anything still debated is marked as such rather than presented as settled.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
| Property | Value | Notes |
|---|---|---|
| Reconstitution solvent | Sterile water or aqueous buffer | Aseptic technique recommended |
| Post-reconstitution storage | 2–8 °C short term; frozen for longer periods | Avoid repeated freeze-thaw cycles |
| Typical purity assay | Reversed-phase HPLC | Peak area used to estimate purity |
| Identity confirmation | Mass measurement | Compares observed value with expected mass |
| Main degradation routes | Hydrolysis and oxidation | Accelerated by heat and extreme pH |
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
A statement from Hooters of America by Ericka Whitaker (Hooters of America senior brand manager) stated that she had no issue of having blonde highlights as a Hooters Girl prior to becoming a brand manager and the company will continue to diversify its employees, from the restaurant to the annual Hooters International Swimsuit Pageant. On September 11, 2017, former Philadelphia-area Hooters waitress Jade Velez filed a lawsuit against Hooters alleging she was a victim of workplace sexual assault by a former kitchen employee. The lawsuit named the employee, three former managers at the Northeast Philadelphia Hooters restaurant where she worked, and Hooters of America, LLC et al as defendants. As of July 2020, the outcome of the case was still pending. On July 16, 2019, Scott Peterson, who was one of two men who alleged they were sexually harassed by a male boss while working for Hooters in the Los Angeles area, reached a settlement with the restaurant chain in the Los Angeles Superior Court, though terms of the settlement were not publicly revealed. The other plaintiff, Paul "PJ" Cagnina, obtained a settlement in May 2017. On August 22, 2024, Hendrick Motorsports of NASCAR announced that they would sue Hooters for $1.705 million plus unpaid sponsorship fees. On March 21, 2025, it was reported that Hooters agreed to pay $900K to Hendrick Motorsports. On October 22, 2024, Hooters of America settled a claim from the Equal Employment Opportunity Commission that black employees were not recalled back to work after the COVID-19 pandemic at the same levels as white employees.
Arg Pro Lys Pro Gln Gln Phe Phe Gly Leu Met (RPKPQQFFGLM) with an amide group at the C-terminus. Substance P is released from the terminals of specific sensory nerves. It is found in the brain and spinal cord and is associated with inflammatory processes and pain.
==== Types of drug controls ==== There are two different types of controls that can be conducted in competition or in training. It is important that tests are conducted by independent organizations that treat each athlete equally, indifferent of fame or nationality.
=== Equilibrative nucleoside transporters (ENTs) === The nucleoside transporters, or equilibrative nucleoside transporters, are uniporters that transport nucleosides, nucleobases, and therapeutic drugs across the cell membrane. Nucleosides serve as building blocks for nucleic acid synthesis and are key components for energy metabolism in creating ATP/ GTP. They also act as ligands for purinergic receptors such as adenosine and inosine. ENTs allow the transport of nucleosides down their concentration gradient. They also have the ability to deliver nucleoside analogs to intracellular targets for the treatment of tumors and viral infections. ENTs are part of the Major Facilitator Superfamily (MFS) and are suggested to transport nucleosides using a clamp-and-switch model. In this model, the substrate first binds to the transporter, which leads to a conformational change that forms an occluded state (clamp). Then, the transporter switches to face the other side of the membrane and releases the bound substrate (switching). ENTs have been found in protozoa and mammals. In humans, they have been discovered as ENT3 (hENT1-3) and ENT4 (hENT4) transporters. ENTs are expressed across all tissue types, but certain ENT proteins have been found to be more abundant in specific tissues. hENT1 is found mostly in the adrenal glands, ovary, stomach and small intestines. hENT2 is expressed mostly in neurological tissues and small parts of the skin, placenta, urinary bladder, heart muscle and gallbladder.
Sources: en.wikipedia.org
Hydrophobins have been found to be structurally and functionally similar to cerato-platanins, another group of small cysteine-rich proteins, which also contain a high percentage of hydrophobic amino acids, and are also associated with hyphal growth. This family of proteins includes the rodlet proteins of Neurospora crassa (gene eas) and Emericella nidulans (gene rodA), these proteins are the main component of the hydrophobic sheath covering the surface of many fungal spores. Genomic sequencing of two fungi from dry or salty environments (Wallemia sebi and W. ichthyophaga) revealed that these species contain predicted hydrophobins with unusually high proportion of acidic amino acids and therefore with potentially novel characteristics. High proportion of acidic amino acids is thought to be an adaptation of proteins to high concentrations of salt.
A glucoside is a glycoside that is chemically derived from glucose. Glucosides are common in plants, but rare in animals. Glucose is produced when a glucoside is hydrolysed by purely chemical means, or decomposed by fermentation or enzymes. The name was originally given to plant products of this nature, in which the other part of the molecule was, in the greater number of cases, an aromatic aldehydic or phenolic compound (exceptions are Jinigrin and Jalapin or Scammonin). It has now been extended to include synthetic ethers, such as those obtained by acting on alcoholic glucose solutions with hydrochloric acid, and also the polysaccharoses, e.g. cane sugar, which appear to be ethers also. Although glucose is the most common sugar present in glucosides, many are known which yield rhamnose or iso-dulcite; these may be termed pentosides. Much attention has been given to the non-sugar parts (aglycone) of the molecules; the constitutions of many have been determined, and the compounds synthesized; and in some cases the preparation of the synthetic glucoside effected. The simplest glucosides are the alkyl ethers which have been obtained by reacting hydrochloric acid on alcoholic glucose solutions. A better method of preparation is to dissolve solid anhydrous glucose in methanol containing hydrochloric acid. A mixture of alpha- and beta-methylglucoside results. The classification of glucosides is a matter of some intricacy.
EF-Tu is a monomeric protein with molecular weight around 43 kDa in Escherichia coli. The protein consists of three structural domains: a GTP-binding domain and two oligonucleotide-binding domains, often referred to as domain 2 and domain 3. The N-terminal domain I of EF-Tu is the GTP-binding domain. It consists of a six beta-strand core flanked by six alpha-helices. Domains II and III of EF-Tu, the oligonucleotide-binding domains, both adopt beta-barrel structures. The GTP-binding domain I undergoes a dramatic conformational change upon GTP hydrolysis to GDP, allowing EF-Tu to dissociate from aa-tRNA and leave the ribosome. Reactivation of EF-Tu is achieved by GTP binding in the cytoplasm, which leads to a significant conformational change that reactivates the tRNA-binding site of EF-Tu. In particular, GTP binding to EF-Tu results in a ~90° rotation of domain I relative to domains II and III, exposing the residues of the tRNA-binding active site. Domain 2 adopts a beta-barrel structure, and is involved in binding to charged tRNA. This domain is structurally related to the C-terminal domain of EF2, to which it displays weak sequence similarity. This domain is also found in other proteins such as translation initiation factor IF-2 and tetracycline-resistance proteins. Domain 3 represents the C-terminal domain, which adopts a beta-barrel structure, and is involved in binding to both charged tRNA and to EF1B (or EF-Ts).
== Biography == Meyer was born on 4 September 1899 in Kerpen, Germany. He studied medicine and received his Ph.D. from the University of Cologne in 1924. He moved to Berlin and received a Ph.D. in chemistry from the Kaiser Wilhelm Society in 1927. In 1930, Herbert Evans invited Meyer to work as assistant professor at the University of California, Berkeley. He then moved to New York and worked at Columbia University, doing research on hyaluronan. From 1967 to 1976, Meyer was a professor of Biochemistry at Yeshiva University in New York City before returning to Columbia University as an emeritus professor. A resident of Teaneck, New Jersey, Meyer died at the age of 90 on 18 May 1990, at a nursing home in nearby Cresskill.
=== Release mechanism === Peptide's release occurs primarily in a calcium-dependent manner through exocytosis of large dense core vesicles in the presynaptic terminal. Big dynorphin immunoreactivity has been detected in regions such as the nucleus accumbens, caudate nucleus, and hippocampus, with significant levels detected in cerebrospinal fluid. The ratio of big dynorphin to dynorphin B in human brain tissue is approximately 1:3.
Sources: en.wikipedia.org
=== Financial considerations === Breastfeeding is less costly than alternatives, but the mother generally must eat more food than would otherwise be necessary. In the US, the extra money spent on food (about US $18 each week) is usually about half the cost of infant formula. According to the CDC, breastfeeding mothers need an extra 450 to 500 calories per day compared to their pre-pregnancy caloric intake. Breastfeeding reduces health care costs and the cost of caring for sick babies. Parents of breastfed babies are less likely to miss work and lose income because their babies are sick. Looking at three of the most common infant illnesses, lower respiratory tract illnesses, otitis media, and gastrointestinal illness, one study compared infants who had been exclusively breastfed for at least three months to those who had not. It found that in the first year of life, there were 2033 excess office visits, 212 excess days of hospitalization, and 609 excess prescriptions for these three illnesses per 1000 never-breastfed infants compared with 1000 infants exclusively breastfed for at least 3 months. However, in a study of over 140,000 newborns in the first month of life, exclusively breastfed newborns had higher hospital readmission rates than those exclusively formula fed, and those exclusively breastfed also had more neonatal outpatient visits compared to those exclusively formula fed.
== History == 3M (then the Minnesota Mining and Manufacturing Company) began producing PFOA by electrochemical fluorination in 1947. Starting in 1951, DuPont purchased PFOA from 3M for use in the manufacturing of specific fluoropolymers—commercially branded as Teflon—but DuPont internally referred to PFOA as C8. In 1968, organofluorine content was detected in the blood serum of consumers, and in 1976 it was suggested to be PFOA or a related compound such as PFOS. In 1999, EPA ordered companies to examine the effects of perfluorinated chemicals after receiving data on the global distribution and toxicity of PFOS. For these reasons, and EPA pressure, in May 2000, 3M announced the phaseout of the production of PFOA, PFOS, and PFOS-related products—the company's best-selling repellent. 3M stated that they would have made the same decision regardless of EPA pressure. Because of the 3M phaseout, in 2002, DuPont built its own plant in Fayetteville, North Carolina, to manufacture the chemical. The chemical has received attention due to litigation from the PFOA-contaminated community around DuPont's Washington Works facility in Washington, West Virginia, along with EPA focus. In 2004, ChemRisk—an "industry risk assessor" that had been contracted by Dupont, reported that over 1.7 million pounds of C8 had been "dumped, poured and released" into the environment from Dupont's Parkersburg, West Virginia-based Washington Works plant between 1951 and 2003.
Amplifications (or gene duplications) or repetition of a chromosomal segment or presence of extra piece of a chromosome broken piece of a chromosome may become attached to a homologous or non-homologous chromosome so that some of the genes are present in more than two doses leading to multiple copies of all chromosomal regions, increasing the dosage of the genes located within them. In some cases, only a fraction of a gene is duplicated, producing a gene shorter that the original. In others, the duplicated gene (or fraction of gene) is copied and inserted right after the original DNA sequence (a tandem duplication) resulting in a longer gene. In the long rung, such multiplicative phenomena dominate the distribution of gene lengths. Polyploidy, duplication of entire sets of chromosomes, potentially resulting in a separate breeding population and speciation. Deletions of large chromosomal regions, leading to loss of the genes within those regions. Mutations whose effect is to juxtapose previously separate pieces of DNA, potentially bringing together separate genes to form functionally distinct fusion genes (e.g., bcr-abl). Large scale changes to the structure of chromosomes called chromosomal rearrangement that can lead to a decrease of fitness but also to speciation in isolated, inbred populations. These include: Chromosomal translocations: interchange of genetic parts from nonhomologous chromosomes. Chromosomal inversions: reversing the orientation of a chromosomal segment. Non-homologous chromosomal crossover.
1985–1987 – 1.3 L (1,296 cc) E3, 2 barrel, 8-valve, 74 PS (54 kW; 73 hp) Gross / 10.5 kg⋅m (103 N⋅m; 76 lb⋅ft) 1987–1989 – 1.3 L (1,323 cc) B3, 2 barrel, 8-valve, 67 PS (49 kW; 66 hp) Net / 10.4 kg⋅m (102 N⋅m; 75 lb⋅ft) 1985–1987 – 1.5 L (1,490 cc) E5, 2 barrel carburettor, 8-valve, 85 PS (63 kW; 84 hp) Gross / 12.3 kg⋅m (121 N⋅m; 89 lb⋅ft) Gross – Net rating 70 PS (51 kW; 69 hp) / 11.2 kg⋅m (110 N⋅m; 81 lb⋅ft) 1985–1987 – 1.5 L (1,490 cc) E5, EGi, 8-valve, 95 PS (70 kW; 94 hp) Gross/12.6 kg⋅m (124 N⋅m; 91 lb⋅ft) Gross – Net rating 76 PS (56 kW; 75 hp) / 11.6 kg⋅m (114 N⋅m; 84 lb⋅ft) 1985–1987 – 1.5 L (1,490 cc) E5T, turbo EGi, 8-valve, 115 PS (85 kW; 113 hp) Gross / 16.5 kg⋅m (162 N⋅m; 119 lb⋅ft) 1987–1989 – 1.5 L (1,498 cc) B5, 2 barrel, 12-valve, 76 PS (56 kW; 75 hp) Net / 11.4 kg⋅m (112 N⋅m; 82 lb⋅ft) 1987–1989 – 1.6 L (1,597 cc) B6, EGi, 8-valve, 85 PS (63 kW; 84 hp) Net / 12.5 kg⋅m (123 N⋅m; 90 lb⋅ft) 1986–1989 – 1.6 L (1,597 cc) B6D, EGi, 16-valve, 110 PS (81 kW; 108 hp) Net / 13.5 kg⋅m (132 N⋅m; 98 lb⋅ft) 1985–1989 – 1.6 L (1,597 cc) B6T, turbo EGi, 16-valve, 140 PS (103 kW; 138 hp) Net / 19.0 kg⋅m (186 N⋅m; 137 lb⋅ft) 1985–1989 – 1.7 L (1,720 cc) PN, diesel, 8-valve, 59 PS (43 kW; 58 hp) Gross / 10.8 kg⋅m (106 N⋅m; 78 lb⋅ft) Gross – Net rating 55 PS (40 kW; 54 hp) / 10.2 kg⋅m (100 N⋅m; 74 lb⋅ft), 1987–1989; Net rating: 58 PS (43 kW; 57 hp) / 10.7 kg⋅m (105 N⋅m; 77 lb⋅ft)
Sources: en.wikipedia.org
Standard practice is a desiccated container at −20 °C, protected from light and kept sealed between uses. Letting the vial reach room temperature before opening reduces condensation on the powder. Repeated warming and cooling of the whole container is generally avoided.
There is no broadly accepted figure for TB-500. Laboratory practice is short-term storage at 2–8 °C with longer-term aliquots frozen, and degradation is expected to increase with time and temperature. Users typically rely on their own stability checks rather than published data.
Mass measurement provides the clearest confirmation by matching an observed value to the expected one. Reversed-phase chromatography adds a purity estimate through peak integration. Combining both is standard because neither alone establishes identity and purity together.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.